- Investing.com
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Metrics to compare | TRVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRVNPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.1x | −0.5x | |
PEG Ratio | 0.00 | −0.08 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | 0.4x | 8.8x | 3.3x | |
Upside (Analyst Target) | - | 85.1% | 43.4% | |
Fair Value Upside | Unlock | 18.5% | 7.1% | Unlock |